Publications by authors named "Graziana Petracca"
Article Synopsis
- This study investigates the relationship between plasma leucine-rich α-2 glycoprotein 1 (LRG1), a proinflammatory molecule, and plasma ceramides in postmenopausal women with type 2 diabetes mellitus (T2DM).
- It measured six specific ceramides, known to be linked to cardiovascular risk, among a group of 99 non-insulin-treated postmenopausal women with an average age of 72.
- The findings indicate that higher levels of LRG1 are significantly associated with increased concentrations of certain ceramides, even after accounting for other health factors.
Article Synopsis
- Recent studies suggest a link between non-alcoholic fatty liver disease (NAFLD) and a higher risk of developing new-onset heart failure (HF), but the extent of this risk and its relation to liver disease severity is unclear.
- A meta-analysis of 11 studies involving over 11 million middle-aged individuals found that NAFLD increases the risk of new-onset HF by about 50%, independent of other health factors like age, sex, and existing cardiovascular risks.
- The findings highlight a significant association, but further research is needed to establish causation due to the observational nature of the studies.
Article Synopsis
- The study investigates the relationship between serum uric acid (SUA) levels and N-terminal pro-B-type natriuretic peptide (NT-proBNP) concentrations in patients with coronary artery disease (CAD) who do not have heart failure.
- A total of 171 patients were analyzed, revealing that those in the highest SUA group had significantly higher NT-proBNP levels compared to lower SUA groups, even after considering various health factors.
- The findings suggest that elevated SUA levels are linked to increased NT-proBNP concentrations in CAD patients, indicating a potential health risk, irrespective of other cardiovascular factors.
Article Synopsis
- A meta-analysis examined the link between non-alcoholic fatty liver disease (NAFLD) and the risk of cardiovascular disease (CVD) events in adults, finding a significant association.
- The study included 36 longitudinal studies with over 5 million participants, revealing that NAFLD increased the risk of fatal and non-fatal CVD events by 45%, and this risk intensified with the severity of NAFLD.
- The findings indicate that the risk persists regardless of other factors like age, sex, and common cardiometabolic issues, emphasizing NAFLD as a serious health concern related to CVD.
Article Synopsis
- A meta-analysis of observational studies was conducted to examine the link between non-alcoholic fatty liver disease (NAFLD) and the risk of developing extrahepatic cancers, using data from 10 studies involving over 182,000 middle-aged individuals.
- It was found that NAFLD significantly increases the risk of various cancers, particularly gastrointestinal cancers (1.5 to 2 times higher risk) and other cancers like lung and breast cancer (1.2 to 1.5 times higher risk).
- The study concluded that while NAFLD is linked to a moderately increased long-term cancer risk, further research is needed to understand how NAFLD contributes to cancer development.
To assess the efficacy of glucagon-like peptide-1 receptor agonists (GLP-1 RAs) for treatment of nonalcoholic fatty liver disease (NAFLD) or steatohepatitis (NASH), we performed a systematic review and meta-analysis of randomized controlled trials (RCTs). Three large electronic databases were systematically searched (up to 15 December 2020) to identify placebo-controlled or active-controlled RCTs using different GLP-1 RAs. We included eleven placebo-controlled or active-controlled phase-2 RCTs (involving a total of 936 middle-aged individuals) that used liraglutide ( = 6 RCTs), exenatide ( = 3 RCTs), dulaglutide ( = 1 RCT) or semaglutide ( = 1 RCT) to specifically treat NAFLD or NASH, detected by liver biopsy ( = 2 RCTs) or imaging techniques ( = 9 RCTs).
View Article and Find Full Text PDFRecent randomized controlled trials (RCTs) tested the efficacy of sodium-glucose cotransporter-2 (SGLT-2) inhibitors to specifically treat nonalcoholic fatty liver disease (NAFLD). We systematically searched three electronic databases (up to 31 October 2020) for identifying placebo-controlled or head-to-head RCTs that used SGLT-2 inhibitors for treatment of NAFLD. No published RCTs with paired liver biopsy data were available for the meta-analysis.
View Article and Find Full Text PDFObjective: Studies reported a significant association between non-alcoholic fatty liver disease (NAFLD) and increased risk of chronic kidney disease (CKD). However, whether this risk changes with increasing severity of NAFLD remains uncertain. We performed a meta-analysis of observational studies to quantify the magnitude of the association between NAFLD and risk of incident CKD.
View Article and Find Full Text PDFObjective: Follow-up studies have shown that non-alcoholic fatty liver disease (NAFLD) is associated with an increased risk of incident diabetes, but currently, it is uncertain whether this risk changes with increasing severity of NAFLD. We performed a meta-analysis of relevant studies to quantify the magnitude of the association between NAFLD and risk of incident diabetes.
Design: We systematically searched PubMed, Scopus and Web of Science databases from January 2000 to June 2020 using predefined keywords to identify observational studies with a follow-up duration of at least 1 year, in which NAFLD was diagnosed by imaging techniques or biopsy.